Lv4
680 积分 2024-10-28 加入
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression
3天前
已完结
Updates and Controversies in the Management of Uterine Serous Carcinoma and Uterine Carcinosarcoma
13天前
已关闭
Sacituzumab Govitecan In Platinum-Resistant Epithelial Ovarian Cancer In A Real-Life Clinical Setting
13天前
已关闭
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
15天前
已完结
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
23天前
已完结
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials
25天前
已完结
Image-guided brachytherapy in cervical cancer including fractionation
26天前
已完结
ZNFX1 functions as a master regulator of epigenetically induced pathogen mimicry and inflammasome signaling in cancer
1个月前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
1个月前
已完结
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
1个月前
已完结
皖公网安备34019202002308
